Liraglutide
- Generic Name
- Liraglutide
- Brand Names
- Saxenda, Victoza, Xultophy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 204656-20-2
- Unique Ingredient Identifier
- 839I73S42A
- Background
Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist. Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining...
- Indication
Saxenda, a formulation of liraglutide intended for weight loss, is indicated as an adjunct to diet and exercise for chronic weight management in adult patients who are obese (BMI≥30 kg/m), or who are overweight (BMI≥27 kg/m) and have at least one weight-related comorbidity. It is also indicated for chronic weight management in pediatric patients ≥12 years ol...
- Associated Conditions
- Major Adverse Cardiovascular Events, Type 2 Diabetes Mellitus
- Associated Therapies
- Chronic Weight Management therapy
A Study of Tirzepatide in Overweight and Very Overweight Participants
- Conditions
- Interventions
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 114
- Registration Number
- NCT04311411
- Locations
- 🇺🇸
Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States
🇺🇸Indiana University School of Medicine, Indianapolis, Indiana, United States
🇺🇸Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Clinical Study on the Improvement of Diabetic Neuropathic Pain by Liraglutide
- First Posted Date
- 2019-10-24
- Last Posted Date
- 2019-10-25
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 60
- Registration Number
- NCT04137328
Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie Diet
- First Posted Date
- 2019-10-10
- Last Posted Date
- 2020-11-02
- Lead Sponsor
- Signe Torekov
- Target Recruit Count
- 215
- Registration Number
- NCT04122716
- Locations
- 🇩🇰
University of Copenhagen, Department of Biomedical Sciences, Copenhagen, Denmark
Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity
- Conditions
- Interventions
- First Posted Date
- 2019-08-29
- Last Posted Date
- 2023-05-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 338
- Registration Number
- NCT04074161
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Olympia, Washington, United States
A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 26774
- Registration Number
- NCT03993132
- Locations
- 🇩🇰
Department of Clinical Epidemiology - Aarhus Unversiteteshospital, Aarhus, Denmark
Effects of Benaglutide on Weight and Gut Microbiota in Obese Patients
- First Posted Date
- 2019-06-14
- Last Posted Date
- 2021-04-09
- Lead Sponsor
- Xiangya Hospital of Central South University
- Target Recruit Count
- 60
- Registration Number
- NCT03986008
- Locations
- 🇨🇳
Xiangya Hospital of Central South University, Changsha, Hunan, China
Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- First Affiliated Hospital of Jinan University
- Target Recruit Count
- 1708
- Registration Number
- NCT03948347
- Locations
- 🇨🇳
The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
Replication of the LEADER Diabetes Trial in Healthcare Claims
- First Posted Date
- 2019-05-03
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 168690
- Registration Number
- NCT03936049
- Locations
- 🇺🇸
Brigham And Women's Hospital, Boston, Massachusetts, United States
A Research Study Looking at How Victoza® Works in People With Type 2 Diabetes in Iran, Followed in Local Clinical Routine
- First Posted Date
- 2019-03-25
- Last Posted Date
- 2021-07-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 839
- Registration Number
- NCT03888157
- Locations
- 🇮🇷
Novo Nordisk Investigational Site, Yazd, Iran, Islamic Republic of
Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)
- First Posted Date
- 2019-03-20
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 60
- Registration Number
- NCT03883412
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.